Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27562953 | 0.85 | CYP3A4 (0.41) | AKR1C3AKR1C2S1PR1MEN1KMT2A | |
| SCHEMBL14829817 | 0.84 | ALDH1A1 (0.45) | AKR1C3AKR1C2TYRSLC6A3ALDH1A1 | |
| SCHEMBL27711085 | 0.82 | LMNA (0.39) | TYRPTGS2ALDH1A1LMNAPTGS1 | |
| SCHEMBL27799748 | 0.79 | S1PR1 (0.38) | S1PR1TYRALDH1A1LMNAHTT | |
| SCHEMBL27753244 | 0.79 | APP (0.41) | S1PR1TYRSLC6A3GPR139 | |
| SCHEMBL4621988 | 0.79 | S1PR1 (0.38) | AKR1C3AKR1C2S1PR1MEN1PKM | |
| SCHEMBL1104688 | 0.77 | LMNA (0.52) | AKR1C3AKR1C2S1PR1MEN1PKM | |
| SCHEMBL10266238 | 0.77 | CYP3A4 (0.43) | TYRMAPK1ALDH1A1LMNAHTT | |
| SCHEMBL28791674 | 0.77 | CHRNA1 (0.37) | MEN1PKMKMT2ATYRSLC6A3 | |
| SCHEMBL27769717 | 0.77 | AKR1C3 (0.39) | AKR1C3AKR1C2TYRPTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | claimed |
| EP-3219717-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8343992-B2 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| CN-101208344-B | (R) -N-methylnaltrexone, method for the synthesis thereof and pharmaceutical use thereof | PROGENICS PHARM INC | 2012-10-24 | — | — | CN | disclosed |
| CN-102741227-A | Aryl benzylamine compounds | NOVARTIS AG | 2012-10-17 | — | — | CN | disclosed |
| EP-0036426-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES. | INTERX RESEARCH CORP (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | disclosed |
| US-4275219-A | Novel process and intermediates useful in the preparation of sympathomimetic amines | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| WO-1981000849-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORP (US) | 1981-04-02 | — | — | WO | disclosed |
| US-RE30241-E | BRONCHODILATION, ADRENERGIC STIMULANTS | STERLING DRUG INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4145441-A | SYMPATHOMIMETIC AMINES EXHIBITING ANTI-HEMORRHOIDAL ACTIVITY | INTERX RESEARCH CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4094983-A | \"KETO\" SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4035405-A | Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | AKR1C3 1620/4885AKR1C2 2202/4885S1PR1 1653/4885 |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | AKR1C3 1644/4885AKR1C2 2119/4885S1PR1 1562/4885 |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | AKR1C3 1644/4885AKR1C2 2119/4885S1PR1 1562/4885 |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | AKR1C3 1644/4885AKR1C2 2119/4885S1PR1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.